TITLE:
Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17

CONDITION:
Neutropenia

INTERVENTION:
Anidulafungin

SUMMARY:

      Anidulafungin is a medicine being developed for treatment of adults with certain kinds of
      fungal infections. This study is evaluating anidulafungin in children and adolescents who
      have fever and a low white blood cell count (neutropenia).
    

DETAILED DESCRIPTION:

      Anidulafungin is an investigational drug being developed as an intravenous treatment for
      esophageal candidiasis, candidemia and other invasive fungal infections. Anidulafungin is an
      antifungal agent of the echinocandin class, which targets the fungal cell wall of yeast and
      other filamentous fungi.
    

ELIGIBILITY:
Gender: All
Age: 2 Years to 17 Years
Criteria:

        -  Children ages 2-17 years with fever and neutropenia.

          -  The expected duration of neutropenia should be 10 days and due to cytotoxic
             chemotherapy or aplastic anemia.
      
